Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)

Phase 2

Not yet recruiting

• Conditions: Dengue
• Interventions: Drug: Emetine Hydrochloride 6mg; Drug: Emetine Hydrochloride 12mg; Drug: Placebo

• Registration Number: NCT07016321
• Lead Sponsor: Johns Hopkins University

Brief Summary

The goal of this study is to evaluate the efficacy and safety of emetine administered orally for symptomatic patients aged 18-65 years infected with the dengue virus. The main questions it aims to answer are:

1. Does emetine reduce 28-day mortality or progression to severe dengue (severe plasma leakage, severe bleeding, or severe organ involvement)?

2. What are the safety outcomes of emetine, including serious adverse events and toxicities?

Participants will be asked to:

1. Take either 6mg emetine, 12mg emetine, or a placebo pill for 7 consecutive days as part of the treatment regimen.

2. Have blood samples taken for at least 5 days to monitor viral load, inflammatory markers, and safety parameters.

3. Be monitored by healthcare staff for daily vital signs and symptoms for clinical assessments for 28 days.

Detailed Description

Dengue fever is a mosquito-borne viral infection caused by the dengue virus (DENV), which belongs to the Flaviviridae family. It is transmitted primarily by Aedes aegypti and Aedes albopictus mosquitoes. Dengue is recognized as one of the top ten global public health threats, affecting an estimated 390 million people annually, with approximately 96 million cases manifesting clinically. Globally, dengue has seen a significant rise in incidence, with a 30-fold increase in the past 50 years. There is currently no antiviral agent proven to work against it. Dengue fever is endemic in Nepal with cyclical outbreaks. The country relies on supportive treatment. This often includes intravenous fluids and, in rare cases, steroids and organ support. Effective antiviral agents could significantly reduce the burden of dengue by preventing disease progression and reducing transmission.

In vitro and in vivo studies have suggested strong antiviral activity of emetine against SARS-CoV-2, dengue, Ebola, cytomegalovirus, and several other viruses. Low et al. had carefully demonstrated that emetine inhibited all four serotypes of DENV infection in cell lines by inhibiting the viral RNA synthesis or the viral protein translation pathway. In the past, emetine, an alkaloid extracted from ipecacuanha roots, has been widely used in the human treatment of amoebic dysentery, amoebic liver abscess, and several viruses such as herpes simplex, herpes zoster, influenza, hepatitis, and mumps. Because of cardiotoxicity (cardiac dysrhythmias), emetine was replaced by metronidazole. The toxicity was unequivocally associated with high-dose emetine (60 mg/day for 10 days to achieve an minimum inhibitory concentration (MIC) of 25 micromol (µM) against Entamoeba histolytica; however, the cardiovascular side-effects were minimal or none when emetine was used for various indications in low dose (\<20 mg/day). The investigators have recently shown that by lowering the standard amoebicidal dose by a factor of 10, emetine can inhibit viral replication while avoiding cardiovascular toxicity.

Phase 1 and 2 studies have been previously carried out. The investigators' clinical trial to evaluate emetine against SARS-CoV-2 is currently approved by Johns Hopkins Medicine (JHM) Institutional Review Board (IRB) (IRB00283778) and is ongoing in Nepal. The investigators have enrolled a few patients in this trial and have not encountered any toxicity. Given the broad-spectrum antiviral activity of emetine, the investigators now plan to evaluate emetine's efficacy and safety in the treatment of symptomatic dengue fever in a clinical trial. The investigators hypothesize that emetine will be efficacious against dengue at low doses. By evaluating its efficacy against dengue, this research can directly inform treatment strategies for patients in over 100 countries, since about 50% of the global population is at risk of dengue fever. In the past, emetine was an essential World Health Organization (WHO)- and FDA-approved drug.

Study Timeline

• Study First Submitted: 2025-05-20
• Status Verified: 2025-06
• Study First Submitted QC: 2025-06-03
• Last Update Submitted: 2025-06-03
• Study First Posted: 2025-06-11
• Last Update Posted: 2025-06-11
• Study Start: 2025-09-01
• Primary Completion: 2029-03-01
• Study Completion: 2029-05-03

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

1. Age 18 to 65 years
2. Admitted to the hospital
3. Laboratory-confirmed infection with dengue virus within the last 5 days and preferably within the last 3 days. Testing for dengue virus using positive Nonstructural protein 1(NS1) strip assay or reverse-transcriptase polymerase chain reaction (RT-PCR)
4. Having two or more clinical symptoms (fever, headache, retro-orbital pain, myalgia, arthralgia, rash, hemorrhagic manifestations, or leucopenia, gastrointestinal symptoms) with the onset of fever within 72 hours of presentation, and
5. Able to provide voluntary informed consent and comply with all study procedures and visits.

Exclusion Criteria

1. Age ≥65 years
2. Pregnant or breastfeeding
3. Current or recent use of the study drug
4. Known allergy to study drug
5. Current or planned participation in another pharmacological interventional trial in the next 10 days
6. Participants with known past history of dengue infection
7. Participants on aspirin, anticoagulants, or with other conditions that might increase the risk of bleeding
8. Participants on immunosuppressive agents, including long-term steroids
9. Severe dengue as defined by the WHO 2009 revised case classification.
10. Individuals with long-term immunosuppressive agents such as anti-cancer chemotherapy or radiation therapy within the past 6 months, or those on systemic corticosteroid therapy
11. History of prior vaccination against dengue fever within one year.
12. Patients who have recently used ayurvedic or herbal medications for dengue or any other conditions in the last 7 days (eg, Papaya leaf extract)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Emetine 6 mg	Emetine Hydrochloride 6mg	Participants take 6mg Emetine pill for 10 consecutive days
Emetine 12 mg	Emetine Hydrochloride 12mg	Participants take 12mg Emetine pill for 10 consecutive days
Placebo	Placebo	Participant take a placebo for 10 consecutive days

Primary Outcome Measures

Name	Time	Method
Evaluate effectiveness of emetine in dengue patients assessed by 28-day mortality or progression	28 days	28-day mortality or progression to severe dengue, defined as severe plasma leakage, severe bleeding, or severe organ involvement (death and severe dengue will be assessed as a composite outcome)
Safety of emetine assessed by number of adverse events	Up to 28 days	Record serious adverse events and toxicities by organ-system
Safety of emetine assessed by rate of drug discontinuation	Up to 28 days	Evaluate the safety of emetine assessed by rate of drug discontinuation

Secondary Outcome Measures

Name	Time	Method
Recovery (≥ 3 days without symptoms)	Up to 14 days	Sustained resolution of all dengue symptoms for ≥ 3 consecutive days (where the first of those days is considered the date of recovery)
Time to Virologic Clearance of Dengue Virus by Qualitative RT-PCR	Pre-dose (day 0), day 3, and day 5	Time to test negativity that is longitudinally measured by Qualitative real-time polymerase chain reaction (RT-PCR).
Quantitative Viral Load Assessment by RT-PCR Cycle Threshold (Ct) Values	Days 0,3, 5	Measures of the average RT-PCR cycle threshold (Ct) values for dengue virus RNA at specified time points post-randomization.
Changes in inflammatory marker measured by hematocrit	Days 0 to 5	Measure hematocrit in percentage (%) for patients
Changes in inflammatory marker measured by white blood count	Day 0-5	Measure white blood count (WBC) for patients measured per microliter (mcL)
Changes in inflammatory marker measured by reticulocyte count	Day 0-5	Measure reticulocyte count as percentage (%) for patients
Changes in inflammatory marker measured by alanine aminotransferase	Day 0-5	Measure alanine aminotransferase (ALT) for patients in units per liter (U/L)
Changes in inflammatory marker measured by serum bilirubin	Day 0-5	Measure serum bilirubin for patients in milligrams per deciliter (mg/dL)
Changes in inflammatory marker measured by serum albumin	Day 0-5	Measure serum albumin for patients in grams per deciliter (g/dL)
Changes in inflammatory marker measured by C-reactive protein	Day 0-5	Measure C-reactive protein (CRP) for patients in milligrams per liter (mg/L)
Post infection fatigue measured by Fatigue Questionnaire	On Day 28	Fatigue will be measured using the validated 11-item Fatigue Questionnaire (FQ), which assesses both physical (7 items) and mental (4 items) fatigue. Each item is rated on a 4-point Likert scale (0 = none, 3 = severe), with total scores ranging from 0 to 33, where higher scores indicate greater fatigue severity.
Changes in inflammatory marker measured by platelet count	Day 0-5	Measure platelet count for patients measured per microliter (mcL)

Trial Locations

Locations (2)

Johns Hopkins University, Division of Infectious Disease; 🇺🇸 Baltimore, Maryland, United States

Bharatpur Hospital; 🇳🇵 Bharatpur-10, Chitwan, Nepal